Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors

The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer. PACHA (programme en Pharmacie pour l'ACcompagnement des femmes ayant de l'Hormonothérapie Adjuvante) is a community pharmacy-based program aimed at optimizing the experience of AET and its use. The main questions it aims to answer are : * Does the program have an effect on factors expected to influence AET adherence? * Is the program acceptable? * Is the implementation of the program feasible? * What is the feasibility of procedures for carrying out a full-scale study? Participating community pharmacies will be randomized. Pharmacists working in pharmacies assigned to the PACHA group (33 pharmacies) will receive web-based training and manuals to use during their consultations with women having an AET. Recruited women attending these pharmacies will also have access to information and resources about AET (videos, evidence-based booklet). Pharmacists practicing in pharmacies assigned to the control group (33 pharmacies) will provide usual care.

NCT Number	NCT05887102
Lead Sponsor	CHU de Quebec-Universite Laval Collaborators: Canadian Institutes of Health Research (CIHR), Quebec Breast Cancer Foundation
Conditions	Breast Neoplasms, Breast Cancer
Enrollment	66 participants
Start Date	2023-06-07
Primary Completion	2025-03 (estimated)
Study Completion	2025-03 (estimated)
Updated on ClinicalTrials.gov	2024-08-22